Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 411

1.

L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.

Watson HA, Durairaj RRP, Ohme J, Alatsatianos M, Almutairi H, Mohammed RN, Vigar M, Reed SG, Paisey SJ, Marshall C, Gallimore A, Ager A.

Front Immunol. 2019 Jun 12;10:1321. doi: 10.3389/fimmu.2019.01321. eCollection 2019.

2.

A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.

Pitner RA, Durham PG, Stewart IE, Reed SG, Cassell GH, Hickey AJ, Carter D.

J Pharm Sci. 2019 Oct;108(10):3302-3311. doi: 10.1016/j.xphs.2019.05.024. Epub 2019 May 29.

PMID:
31152746
3.

Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.

Amorim FM, Nobre ML, Nascimento LS, Miranda AM, Monteiro GRG, Freire-Neto FP, Queiroz MDCP, Queiroz JW, Duthie MS, Costa MR, Reed SG, Johnson WD Jr, Dupnik KM, Jeronimo SMB.

PLoS Negl Trop Dis. 2019 Jan 28;13(1):e0007089. doi: 10.1371/journal.pntd.0007089. eCollection 2019 Jan.

4.

Mycobacterium leprae Recombinant Antigen Induces High Expression of Multifunction T Lymphocytes and Is Promising as a Specific Vaccine for Leprosy.

Bezerra-Santos M, do Vale-Simon M, Barreto AS, Cazzaniga RA, de Oliveira DT, Barrios MR, Ferreira AR, Santos-Bio NC, Reed SG, de Almeida RP, Corrêa CB, Duthie MS, de Jesus AR.

Front Immunol. 2018 Dec 12;9:2920. doi: 10.3389/fimmu.2018.02920. eCollection 2018.

5.

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.

Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, Smedegaard HH, Ditlev SB, Soegaard M, Poulsen L, Dyring C, Calle CL, Knoblich A, Ibáñez J, Esen M, Deloron P, Ndam N, Issifou S, Houard S, Howard RF, Reed SG, Leroy O, Luty AJF, Theander TG, Kremsner PG, Salanti A, Nielsen MA.

Clin Infect Dis. 2019 Oct 15;69(9):1509-1516. doi: 10.1093/cid/ciy1140.

6.

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology.

Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB.

NPJ Vaccines. 2019 Jan 3;4:1. doi: 10.1038/s41541-018-0094-0. eCollection 2019.

7.

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani.

Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu FC, Stinchcomb DT, Reed SG.

Front Immunol. 2018 Oct 17;9:2420. doi: 10.3389/fimmu.2018.02420. eCollection 2018.

8.

Correlates of GLA family adjuvants' activities.

Reed SG, Carter D, Casper C, Duthie MS, Fox CB.

Semin Immunol. 2018 Oct;39:22-29. doi: 10.1016/j.smim.2018.10.004. Epub 2018 Oct 23. Review.

PMID:
30366662
9.

Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity.

Michaeli A, Mezan S, Kühbacher A, Finkelmeier D, Elias M, Zatsepin M, Reed SG, Duthie MS, Rupp S, Lerner I, Burger-Kentischer A.

J Immunol. 2018 Dec 1;201(11):3383-3391. doi: 10.4049/jimmunol.1800380. Epub 2018 Oct 22.

PMID:
30348734
10.

Second coming: the re-emergence and modernization of immunotherapy by vaccines as a component of leprosy control.

Duthie MS, Casper C, Reed SG.

Future Microbiol. 2018 Oct;13:1449-1451. doi: 10.2217/fmb-2018-0186. Epub 2018 Oct 12. No abstract available.

11.

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN.

NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.

12.

Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.

Zhang WW, Ghosh AK, Mohamath R, Whittle J, Picone A, Lypaczewski P, Ndao M, Howard RF, Das P, Reed SG, Matlashewski G.

BMC Infect Dis. 2018 Oct 3;18(1):500. doi: 10.1186/s12879-018-3420-2.

13.

The adjuvant GLA-AF enhances human intradermal vaccine responses.

Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG.

Sci Adv. 2018 Sep 12;4(9):eaas9930. doi: 10.1126/sciadv.aas9930. eCollection 2018 Sep.

14.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team.

NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.

15.

Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy.

Zhang W, Molehin AJ, Rojo JU, Sudduth J, Ganapathy PK, Kim E, Siddiqui AJ, Freeborn J, Sennoune SR, May J, Lazarus S, Nguyen C, Redman WK, Ahmad G, Torben W, Karmakar S, Le L, Kottapalli KR, Kottapalli P, Wolf RF, Papin JF, Carey D, Gray SA, Bergthold JD, Damian RT, Mayer BT, Marks F, Reed SG, Carter D, Siddiqui AA.

Ann N Y Acad Sci. 2018 Aug;1425(1):38-51. doi: 10.1111/nyas.13942.

16.

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N.

Mol Ther. 2018 Oct 3;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.010. Epub 2018 Aug 2.

17.

Adjuvants.

Carter D, Duthie MS, Reed SG.

Curr Top Microbiol Immunol. 2018 Jul 25. doi: 10.1007/82_2018_112. [Epub ahead of print]

PMID:
30043342
18.

Erratum: Author Correction: LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection.

Duthie MS, Pena MT, Ebenezer GJ, Gillis TP, Sharma R, Cunningham K, Polydefkis M, Maeda Y, Makino M, Truman RW, Reed SG.

NPJ Vaccines. 2018 May 15;3:18. doi: 10.1038/s41541-018-0055-7. eCollection 2018.

19.

Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Singh S, Ramírez-Salazar EG, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, Hamlin C, Rao M, Dayton F, Bear J, Chowdhury B, Alicea C, Lifson JD, Broderick KE, Sardesai NY, Sivananthan SJ, Fox CB, Reed SG, Venzon DJ, Hirsch VM, Pavlakis GN, Felber BK.

J Virol. 2018 Jul 17;92(15). pii: e00281-18. doi: 10.1128/JVI.00281-18. Print 2018 Aug 1.

20.

LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection.

Duthie MS, Pena MT, Ebenezer GJ, Gillis TP, Sharma R, Cunningham K, Polydefkis M, Maeda Y, Makino M, Truman RW, Reed SG.

NPJ Vaccines. 2018 Mar 28;3:12. doi: 10.1038/s41541-018-0050-z. eCollection 2018. Erratum in: NPJ Vaccines. 2018 May 15;3:18.

21.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
22.

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN.

Front Immunol. 2018 Feb 19;9:295. doi: 10.3389/fimmu.2018.00295. eCollection 2018.

23.

Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, Housman M, Bouton-Verville H, Shen X, Trama AM, Scearce R, Sutherland L, Santra S, Newman A, Eaton A, Xu K, Georgiev IS, Joyce MG, Tomaras GD, Bonsignori M, Reed SG, Salazar A, Mascola JR, Moody MA, Cain DW, Centlivre M, Zurawski S, Zurawski G, Erickson HP, Kwong PD, Alam SM, Levy Y, Montefiori DC, Haynes BF.

Cell Rep. 2017 Dec 26;21(13):3681-3690. doi: 10.1016/j.celrep.2017.12.028.

24.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.

NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

25.

Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Cecílio P, Pérez-Cabezas B, Fernández L, Moreno J, Carrillo E, Requena JM, Fichera E, Reed SG, Coler RN, Kamhawi S, Oliveira F, Valenzuela JG, Gradoni L, Glueck R, Gupta G, Cordeiro-da-Silva A.

PLoS Negl Trop Dis. 2017 Nov 27;11(11):e0005951. doi: 10.1371/journal.pntd.0005951. eCollection 2017 Nov.

26.

Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.

Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L.

Nat Commun. 2017 Nov 23;8(1):1732. doi: 10.1038/s41467-017-01336-3.

27.

Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program.

Williams SA, Browne-Ferdinand B, Smart Y, Morella K, Reed SG, Kanter J.

Glob Pediatr Health. 2017 Nov 3;4:2333794X17739191. doi: 10.1177/2333794X17739191. eCollection 2017.

28.

Identification of Novel Antigens Recognized by Serum Antibodies in Bovine Tuberculosis.

Lyashchenko KP, Grandison A, Keskinen K, Sikar-Gang A, Lambotte P, Esfandiari J, Ireton GC, Vallur A, Reed SG, Jones G, Vordermeier HM, Stabel JR, Thacker TC, Palmer MV, Waters WR.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00259-17. doi: 10.1128/CVI.00259-17. Print 2017 Dec.

29.

Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of Visceral Leishmaniasis patients and the monitoring of their response to treatment.

Hossain F, Ghosh P, Khan MAA, Duthie MS, Vallur AC, Picone A, Howard RF, Reed SG, Mondal D.

PLoS One. 2017 Sep 28;12(9):e0185606. doi: 10.1371/journal.pone.0185606. eCollection 2017.

30.

Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.

Yu JS, Liao HX, Pritchett J, Bowman C, Vivian C, Parks R, Xia SM, Cooper M, Williams WB, Bonsignori M, Reed SG, Chen M, Vandergrift N, Rice CM, Haynes BF.

J Virol Methods. 2017 Nov;249:85-93. doi: 10.1016/j.jviromet.2017.08.012. Epub 2017 Aug 31.

31.

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

Allen JD, Owino SO, Carter DM, Crevar CJ, Reese VA, Fox CB, Coler RN, Reed SG, Baldwin SL, Ross TM.

Vaccine. 2017 Sep 12;35(38):5209-5216. doi: 10.1016/j.vaccine.2017.07.107. Epub 2017 Aug 5.

PMID:
28789850
32.

Innovative tools and approaches to end the transmission of Mycobacterium leprae.

Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH.

Lancet Infect Dis. 2017 Sep;17(9):e298-e305. doi: 10.1016/S1473-3099(17)30314-6. Epub 2017 Jul 7. Review.

PMID:
28693856
33.

CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.

Christiaansen AF, Dixit UG, Coler RN, Marie Beckmann A, Reed SG, Winokur PL, Zimmerman MB, Varga SM, Wilson ME.

Vaccine. 2017 Jul 24;35(33):4255-4261. doi: 10.1016/j.vaccine.2017.06.013. Epub 2017 Jun 27.

34.

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.

Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, Balachandran H, Mach LV, Saunders KO, Weiner JA, Scearce R, Sutherland LL, Phogat S, Tartaglia J, Reed SG, Hu SL, Theis JF, Pinter A, Montefiori DC, Kepler TB, Peachman KK, Rao M, Michael NL, Suscovich TJ, Alter G, Ackerman ME, Moody MA, Liao HX, Tomaras G, Ferrari G, Korber BT, Haynes BF.

Nat Commun. 2017 Jun 8;8:15711. doi: 10.1038/ncomms15711.

35.

Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Duthie MS, Reed SG.

Clin Vaccine Immunol. 2017 Jul 5;24(7). pii: e00108-17. doi: 10.1128/CVI.00108-17. Print 2017 Jul. Review.

36.

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D.

Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426.

37.

Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses Associated with the Presentation of Paucibacillary Leprosy and Leprosy Reactions.

Santos MB, de Oliveira DT, Cazzaniga RA, Varjão CS, Dos Santos PL, Santos MLB, Correia CB, Faria DR, Simon MDV, Silva JS, Dutra WO, Reed SG, Duthie MS, de Almeida RP, de Jesus AR.

Scand J Immunol. 2017 Jul;86(1):40-49. doi: 10.1111/sji.12558.

38.

Prenatal vitamin D and enamel hypoplasia in human primary maxillary central incisors: a pilot study.

Reed SG, Voronca D, Wingate JS, Murali M, Lawson AB, Hulsey TC, Ebeling MD, Hollis BW, Wagner CL.

Pediatr Dent J. 2017 Apr;27(1):21-28. doi: 10.1016/j.pdj.2016.08.001. Epub 2016 Dec 19.

39.

sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasis.

Silva RL, Santos MB, Almeida PL, Barros TS, Magalhães L, Cazzaniga RA, Souza PR, Luz NF, França-Costa J, Borges VM, Lima-Junior DS, Lipscomb MW, Duthie MS, Reed SG, Almeida RP, Jesus AR.

PLoS Negl Trop Dis. 2017 Mar 29;11(3):e0005486. doi: 10.1371/journal.pntd.0005486. eCollection 2017 Mar.

40.

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.

Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scearce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool-Karim SS, Cohen M, Liao HX, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, Haynes BF.

Sci Transl Med. 2017 Mar 15;9(381). pii: eaai7521. doi: 10.1126/scitranslmed.aai7521.

41.

The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy.

Fonseca AB, Simon MD, Cazzaniga RA, de Moura TR, de Almeida RP, Duthie MS, Reed SG, de Jesus AR.

Infect Dis Poverty. 2017 Feb 6;6(1):5. doi: 10.1186/s40249-016-0229-3. Review.

42.

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.

Clin Transl Immunology. 2016 Nov 2;5(11):e108. eCollection 2016 Nov.

43.

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants.

Olafsdottir TA, Lindqvist M, Nookaew I, Andersen P, Maertzdorf J, Persson J, Christensen D, Zhang Y, Anderson J, Khoomrung S, Sen P, Agger EM, Coler R, Carter D, Meinke A, Rappuoli R, Kaufmann SH, Reed SG, Harandi AM.

Sci Rep. 2016 Dec 13;6:39097. doi: 10.1038/srep39097.

44.

Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species.

Sato CM, Sanchez MC, Celeste BJ, Duthie MS, Guderian J, Reed SG, de Brito ME, Campos MB, de Souza Encarnação HV, Guerra J, de Mesquita TG, Pinheiro SK, Ramasawmy R, Silveira FT, de Assis Souza M, Goto H.

J Clin Microbiol. 2017 Feb;55(2):495-503. doi: 10.1128/JCM.01904-16. Epub 2016 Dec 7.

45.

The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.

Espinosa DA, Vega-Rodriguez J, Flores-Garcia Y, Noe AR, Muñoz C, Coleman R, Bruck T, Haney K, Stevens A, Retallack D, Allen J, Vedvick TS, Fox CB, Reed SG, Howard RF, Salman AM, Janse CJ, Khan SM, Zavala F, Gutierrez GM.

Infect Immun. 2017 Jan 26;85(2). pii: e00498-16. doi: 10.1128/IAI.00498-16. Print 2017 Feb.

46.

HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.

Bradley T, Yang G, Ilkayeva O, Holl TM, Zhang R, Zhang J, Santra S, Fox CB, Reed SG, Parks R, Bowman CM, Bouton-Verville H, Sutherland LL, Scearce RM, Vandergrift N, Kepler TB, Moody MA, Liao HX, Alam SM, McLendon R, Everitt JI, Newgard CB, Verkoczy L, Kelsoe G, Haynes BF.

J Immunol. 2016 Dec 15;197(12):4663-4673. Epub 2016 Nov 14.

47.

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.

48.

Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.

van Haren SD, Dowling DJ, Foppen W, Christensen D, Andersen P, Reed SG, Hershberg RM, Baden LR, Levy O.

J Immunol. 2016 Dec 1;197(11):4413-4424. Epub 2016 Oct 28.

49.

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT.

J Immunol. 2016 Dec 1;197(11):4351-4359. Epub 2016 Oct 28.

50.

Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Schaut RG, Grinnage-Pulley TL, Esch KJ, Toepp AJ, Duthie MS, Howard RF, Reed SG, Petersen CA.

Vaccine. 2016 Oct 17;34(44):5225-5234. doi: 10.1016/j.vaccine.2016.09.016. Epub 2016 Sep 21.

Supplemental Content

Support Center